Top Stories

Nepal approves emergency use of ‘Kovishield’ vaccine, requests India to give it soon


Neighboring Nepal has also approved the emergency use of Kovishield after India approved the vaccine ‘Kovishield’ for use by Oxford and Astragenica on January 3. News agency Reuters has quoted this news to the government of Nepal. The Indian Ministry of External Affairs said on Friday that during the sixth meeting of the India-Nepal Joint Commission, Nepal congratulated Kovishield and Kovichen on the success of the product and requested for the earliest vaccine for Nepal.

Nepal has approved the emergency use of Estrogena vaccine at a time when the vaccination of the frontline workers across the country is going to start in India a day later i.e. from 16 January.

On 1 January, on behalf of the Expert Committee in India, for the final approval of emergency use of Kovishield was recommended to the Drugs Controller General of India. After this, on 2 January, ‘Kovaxin’ prepared by Bharat Biotech and ICMR was sent to DCGI by the expert committee to take a final decision. DCGI finally approved the emergency use of both vaccines on 3 January.

According to reports, about 12 million vaccines are going to be demanded from Nepal. India’s vaccine is eagerly awaited in Nepal. Prime Minister of India, Narendra Modi, in telephone talks and video conferencing with the Prime Minister of Nepal, had assured that with the preparation of vaccine in India, Nepalese citizens will be provided with Kovid vaccine on priority.

Foreign Minister of Nepal Pradeep Gwali is on a tour of India. An important objective of Nepal’s Foreign Minister’s visit to Delhi is also to acquire the Corona vaccine. Along with Foreign Minister Gianwali, the Health Secretary is also included in the Delhi tour team, which can sign any agreement on the corona vaccine.

ALSO READ: Nepal’s first high-level visit after the map dispute, Foreign Minister Pradeep Giwali may discuss Delhi influx, vaccine-border dispute today

.

Leave a Reply

Your email address will not be published. Required fields are marked *